Home › Research › Topics › galantamine
galantamine
271 studies tagged galantamine, dated 1981-01-01 to 2026-10-14. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
271 studies carry this tag.
Date range
1981 to 2026
Top journals
- Journal of Alzheimer's disease : JAD 15
- Neurology 11
- Journal of the American Geriatrics Society 9
- Research Square 8
- medRxiv 8
138 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Patients treated with memantine had significantly lower NPI total scores than patients treated with placebo.
-
95 patients assigned donepezil and 99 patients assigned placebo completed the study.
-
These data suggest that AH medications, and specifically potassium-sparing diuretics, are associated with reduced incidence of AD.
-
Cognitive functioning, mood, and health-related QOL were significantly improved following a 24-week course of the acetylcholinesterase inhibitor donepezil.
-
For mild to moderately severe AD, the results of the study suggested that all three treatments were beneficial when assessed using cognitive outcome measures.
-
In a 24-week, randomized, double-blind, placebo-controlled, multicenter study of rivastigmine, 487 patients with dementia associated with Parkinson disease underwent assessment of attention on the Cognitive Drug Research computerized cognitive assessment system before dosing and 16 and 24 weeks later.
-
Because of flawed methods and small clinical benefits, the scientific basis for recommendations of cholinesterase inhibitors for the treatment of Alzheimer's disease is questionable.
-
In total, 994 patients received cholinesterase inhibitor treatment (rivastigmine, n = 495; donepezil, n = 499), and 57.9% of patients completed the study.
-
Donepezil was well tolerated and most adverse events were mild.
-
64/100
For the cohort of patients that remained on therapy > or =60 days, the mean time to treatment discontinuation was 331 days (95% confidence interval [CI], 307-355) for rivastigmine patients (n = 392) versus 337 days (95% CI, 322-352) for donepezil patients (n = 1288).
-
Neither quetiapine nor rivastigmine are effective in the treatment of agitation in people with dementia in institutional care.
-
Inappropriate drug use was common in our study cohort.
-
Fewer than half of the older adults dispensed donepezil in Ontario would have been eligible to participate in the RCTs that established the efficacy of this drug.
-
Cerebrovascular disease (CVD), as well as secondary ischemic brain injury from cardiovascular disease, are common causes of dementia and cognitive decline in the elderly.
-
The incidence of hip fracture appears to be associated with benzodiazepine use.
-
Donepezil has significant efficacy in the treatment of neuropsychiatric symptoms in patients with mild to moderate AD.
-
Cognition averaged 0.8 MMSE (mini-mental state examination) points better (95% CI 0.5-1.2; p<0.0001) and functionality 1.0 BADLS points better (0.5-1.6; p<0.0001) with donepezil over the first 2 years.
-
The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs.
-
Incident use of neuroleptics in Ontario nursing homes is substantial.
-
Behavioural troubles due to frontotemporal dementia (FTD) are difficult to treat.
-
Treatment with ChEIs results in a modest but significant therapeutic effect and modestly but significantly higher rates of adverse events and discontinuation of treatment.
-
36/100
ChE inhibitors provide symptomatic benefit in AD across key symptom domains.
-
Cholinergic dysfunction is also associated with neuropsychiatric and functional deficits, but results from randomized controlled trials of cholinesterase inhibitors are conflicting.
-
55/100
Baseline demographics were similar between the treatment groups.
-
47/100
Seventy-one patients completed the trial.
-
38/100
Nefiracetam (DM-9384) is a cerebral metabolic product under development by Daiichi for the potential treatment of the after-effects of cerebrovascular disorders.
-
This standard is based on the results of large-scale, double-blind, placebo-controlled trials.
-
Community-based, commercially insured, older adults with probable dementia are more likely to take anticholinergics than matched controls.
-
Patients treated with citalopram or perphenazine showed statistically significant improvement on several Neurobehavioral Rating Scale factor scores.
-
56/100
Patients on galantamine, compared with those on placebo, experienced benefits in cognitive function and instrumental and basic activities of daily living.
-
67/100
A Systematic ReviewObstructive sleep apnoea, positive airway pressure treatment and postoperative delirium: protocol for a retrospective observational studyEvidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensusDeprescribiendo para mejorar la salud de las personas o cuando deprescribir puede ser la mejor medicinaThe use of proton pump inhibitors among older adults with intellectual disability: A cross sectional observational studyNeed for Comprehensive Health Care Quality Measures for Older AdultsDevelopment and initial validation of prescribing quality indicators for patients with chronic kidney diseaseOlder patients' prescriptions screening in the community pharmacy: development of the Ghent Older People's Prescriptions community Pharmacy Screening (GheOP³S) toolA New Computer-Based Tool to Reduce Potentially Inappropriate Prescriptions in Hospitalized Geriatric PatientsThe Successful Aging After Elective Surgery Study: Cohort Description and Data Quality ProceduresRoutine deprescribing of chronic medications to combat polypharmacyAnnual Cognitive Assessment for Older Adults: Update for NursesThe impact of pharmaceutical care interventions for medication underuse in older people: a systematic review and meta-analysisAssessing appropriateness of osteoarthritis care using quality indicators: a systematic reviewCurrent Factors of Fragility and Delirium in Vascular SurgeryDrug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologistPrescription of potentially inappropriate drugs for geriatric patients in long-term care: improvement through pharmacist's interventionChanging practice in dementia care in the community: developing and testing evidence-based interventions, from timely diagnosis to end of life (EVIDEM)High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From the Italian Medicines Agency (AIFA)Delirium in elderly peopleDelphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care UnitsPotentiality of STOPP/START criteria used in primary care to effectively change inappropriate prescribing in elderly patientsToo Much to ManageHip Fracture ManagementAppropriateness of Medication Prescribing Using the STOPP/START Criteria in Veterans Receiving Home-Based Primary CareActualización de la neumonía en el ancianoEstablishi
-
Donepezil is the most widely used acetylcholinesterase inhibitor licensed for symptomatic treatment of mild-to-moderate Alzheimer's disease.
-
77/100
Patients treated with galantamine 24 mg/day had a significantly better outcome than placebo on ADAS-cog; the treatment difference was 3 points on the intention-to-treat (ITT) analysis ( p = 0.01) and 4.2 points on per protocol analysis ( p = 0.001).
-
81/100
As the first 1-year, multinational, double-blinded, placebo-controlled study of a cholinesterase inhibitor in AD, these data support donepezil as a well tolerated and effective long-term treatment for patients with AD, with benefits over placebo on global assessment, cognition, and ADL.
-
Donepezil is an effective and safe drug for the long-term symptomatic treatment of mild to moderately severe AD for up to 144 weeks (2.8 years), and sustained treatment may confer some advantages.
-
Faced with increasing demands on demonstrating cost effectiveness, pharmaceutical companies are required to conduct pharmacoeconomic evaluations throughout the drug development programme.
-
Recipients of galantamine 16 or 24 mg/day achieved significant improvements in cognitive and global symptoms relative to placebo recipients in large (n = 285 to 978 patients with mild to moderate AD) well-designed trials of 3 to 6 months' duration.
-
Comparable modest reductions in agitation occurred in patients receiving haloperidol, trazodone, BMT, and placebo.
-
A low-dose regimen of prednisone is not useful in the treatment of AD.
-
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study.
-
43/100
Donepezil has psychotropic properties, and pretreatment behaviors help predict patients' responses to treatment.
-
Subjects taking antihypertensive medication (n = 651, 83.9% of whom took diuretics) had a lower prevalence of dementia than those not taking antihypertensive medication (P<.001).
-
There were no group differences with any of the outcome measures in an intent-to-treat analysis.
-
The results of the cost-effectiveness model presented here suggest that donepezil may be cost-effective but additional controlled data on long-term drug efficacy are needed.
-
At the end of the study cognitive function had deteriorated among those in the placebo group.
-
The results of this trial support the hypothesis that memantine treatment leads to functional improvement and reduces care dependence in severely demented patients.
-
Dementia with Lewy bodies (DLB) is common.
-
Limited to individuals who had been hospitalized in the 6 months preceding the first assessment, Minimum Data Set diagnoses were compared with those on the hospital discharge claims maintained in the Medicare Provider Analysis and Review database.
-
This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.
-
59/100
Although modest, the changes induced by EGb were objectively measured by the ADAS-Cog and were of sufficient magnitude to be recognized by the caregivers in the GERRI.
From across this tag
7 of the 271 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 7. The same 7 appear here every time.
- Assessment of potentially inappropriate medications using STOPPFrail V2 criteria and OncPal guideline in elderly cancer patients with end-stage disease: A cross-sectional study
- Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study
- 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study
- Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia
- Cholinesterase inhibitors-associated torsade de pointes/QT prolongation: a real-world pharmacovigilance study
- Physostigmine and Arecoline: Effects of Intravenous Infusions in Alzheimer Presenile Dementia
- Incretin-Based Drugs and the Risk of Dementia Among Patients with Type 2 Diabetes